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Abstract
Background: Apolipoprotein E (ApoE) is a multifunctional protein, and its deficiency leads to the development of
atherosclerosis in mice. Patients with pulmonary hypertension (PH) have reduced expression of ApoE in lung tissue.
ApoE is known to inhibit endothelial and smooth muscle cell proliferation and has anti-inflammatory and anti-platelet
aggregation properties. Young ApoE-deficient mice have been shown to develop PH on high fat diet. The combined
role of female sex and aging in the development of PH has not been investigated before. Here, we investigated the
development of PH in young and middle-aged (MA) female ApoE-deficient mice and explored the role of exogenous
estrogen (E2) replacement therapy for the aging females.
Methods: Wild type (WT) and ApoE-deficient female mice (Young and MA) were injected with a single intraperitoneal
dose of monocrotaline (MCT, 60 mg/kg). Some ApoE-deficient MA female mice that received MCT were also treated
with subcutaneous E2 pellets (0.03 mg/kg/day) from day 21 to 30 after MCT injection. Direct cardiac catheterization
was performed terminally to record right ventricular systolic pressure (RVSP). Right ventricular (RV), left ventricular (LV),
and interventricular septum (IVS) were dissected and weighed. Lung sections were examined using trichrome and
immunofluorescence staining. Western blot analyses of lung and RV lysates were performed.
Results: In WT female mice, the severity of PH was similar between young and MA mice as RVSP was not significantly
different (RVSP = 38.2 ± 1.2 in young vs. 40.5 ± 8.3 mmHg in MA, p < 0.05). In ApoE-deficient mice, MA females
developed significantly severe PH (RVSP = 63 ± 10 mmHg) compared to young females (RVSP; 36 ± 3 mmHg, p < 0.05
vs. MA female). ApoE-deficient MA females also developed more severe RV hypertrophy compared to young females
(RV hypertrophy index (RV/[LV + IVS]) = 0.53 ± 0.06 vs. 0.33 ± 0.01, p < 0.05). ApoE-deficient MA female mice
manifested increased peripheral pulmonary artery muscularization and pulmonary fibrosis. E2 treatment of MA
female ApoE-deficient mice resulted in a significant decrease in RVSP, reversal of pulmonary vascular remodeling,
and RV hypertrophy. In MA female ApoE-deficient mice with PH, only the expression of ERβ in the lungs, but not
in RV, was significantly downregulated, and it was restored by E2 treatment. The expression of ERα was not
affected in either lungs or RV by PH. GPR30 was only detected in the RV, and it was not affected by PH in MA
female ApoE-deficient mice.
Conclusions: Our results suggest that only aging female ApoE-deficient but not WT mice develop severe PH
compared to younger females. Exogenous estrogen therapy rescued PH and RV hypertrophy in aging female
ApoE-deficient mice possibly through restoration of lung ERβ.
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Background
Pulmonary hypertension (PH) is characterized by arterial
obliteration resulting from excessive proliferation of
pulmonary vascular smooth muscle and endothelial cells
[1]. PH is associated with a progressive elevation in
pulmonary arterial pressure leading to right ventricular
(RV) hypertrophy and RV failure.
Apolipoprotein E (ApoE) is a multifunctional protein
known to reduce circulating oxidized low-density lipo-
proteins and atherogenesis in the vessel wall [2]. ApoE
knockout mice have increased oxidized lipids [3] and
develop atherosclerosis on high fat diet [4]. ApoE is also
known to inhibit endothelial and smooth muscle cell
proliferation [5, 6], key pathologic features of pulmonary
vascular disease [7, 8], and has anti-inflammatory and
anti-platelet aggregation properties [9]. ApoE deficiency
leads to enhanced platelet-derived growth factor signal-
ing, which is important in the pathobiology of PAH [10].
ApoE knockout mice also develop pulmonary hyperten-
sion on high fat diet [10]. Interestingly, patients with
pulmonary arterial hypertension (PAH) have reduced
expression of ApoE in lung tissue [10, 11]. Recently
published studies from our group and others have impli-
cated the involvement of oxidized lipids in the develop-
ment of PH [12–16]. Therefore, ApoE knockout mice
represent a model that is susceptible for the develop-
ment of PH.
Although females are more likely to be diagnosed with
some forms of PH [17], they are also protected against
PH in different animal models [18–20], a phenomenon
known as the “estrogen paradox” of PH [21]. This sex
difference in experimental PH has been suggested to be
in part due to the protective effects of estrogen, as ovari-
ectomy exacerbates PH and pre-treatment/treatment
with estrogen and its metabolites attenuates PH and RV
dysfunction [22–27]. Estrous cyclicity peaks at 7–8
months and starts to decline by 9 months of age, with
cessation of cyclicity occurring between 13 and 16
months of age in mice [28]. Post-menopausal women
have an increased risk for the development of some
forms of PH, [29] and hormone replacement therapy
prevents the progression of PH in these forms of PH
[30]. Other investigators have also suggested that severe
PH has now become overwhelmingly a disease of post-
menopausal women [20]. In fact, despite higher inci-
dence of the disease in female patients as shown in the
REVEAL registry of PH patients, there is a clear shift in
the mean age of diagnosis towards older age, particularly
in the female patients in the USA [31].
Taken together, the shift of PAH patient population
towards post-menopausal women, the decreases of ApoE
in human PAH lung tissue, and the susceptibility of
ApoE-deficient mice to develop PH, makes ApoE-
deficient mice a very interesting model to study the
effect of aging on development of PH in females. Here,
we compared the effect of aging on severity of PH in
ApoE-deficient mice vs. wild type young and MA mice.
We also examined the potential for exogenous estrogen




Female ApoE-deficient mice (young, 7–8 months old)
and middle-aged (MA, 12–13 months old) as well as
female C57BL6 wild type (WT) mice (young, 4 months
old) and MA (14 months old) were used for the study.
We have carefully followed the estrous cycle by checking
vaginal smears in middle-aged mice (ApoE-deficient
mice and WT mice) for 4–5 consecutive days. All MA
mice showed no changes in the estrous cycle, and the
majority of the cells were leukocytes and nucleated
epithelial cell which is consistent with metestrus and
diestrus cytology [32, 33]. So, we confirmed that MA
ApoE-deficient or WT female mice that we used for this
study were not cycling at around 12–14 months of age.
Our finding is in agreement with previous study from Nel-
son et al. in 1995 showing C57/BL6 mice become acyclic
around 12–17 months old [34]. Mice were injected with a
single intraperitoneal dose of MCT (60 mg/kg). MCT has
been shown to induce PH in mice [35–37]. MCT was dis-
solved in 1 N HCl, the pH was adjusted to 7.4 and diluted
with phosphate buffered saline (PBS) before injection.
MCT was injected at day 0 that induced severe PH
by ~day 30.
Some MA female ApoE-deficient mice that were
injected with MCT were treated with subcutaneous con-
tinuous release estrogen (E2) pellets via a subcutaneous
10-day continuous release pellet of 0.03 mg E2/kg/day
(Innovative Research of America, E2 group) from day 21
to 30 after MCT. Some MA female ApoE-deficient mice
were injected with saline and served as controls (CTRL
group). Protocols received institutional review and com-
mittee approval.
Cardiac and pulmonary hemodynamics
The RVSP was measured directly by inserting a catheter
(1.4 F Millar SPR-671, ADInstruments) connected to a
pressure transducer (Power Lab, ADInstruments) into the
RV just before sacrifice. Briefly, for cardiac catheterization,
the mice were anesthetized with a mixture of Ketamine
(80 mg/kg) and Xylazine (8 mg/kg) intraperitoneally. The
animals were placed on a controlled warming pad to keep
the body temperature constant at 37 °C. After a tracheot-
omy was performed, a cannula was inserted, and the ani-
mals were mechanically ventilated. After a midsternal
thoracotomy, mice were placed under a stereomicroscope
(Zeiss, Hamburg, Germany) and a pressure-conductance
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catheter (model 1.4 F Millar SPR-671) was introduced via
the apex into the RV and positioned towards the pulmon-
ary valve. The catheter was connected to a signal proces-
sor (ADInstruments) and RV pressures were recorded
digitally. After recording the pressures, heart and lung
tissues were removed rapidly under deep anesthesia for
preservation of protein integrity.
Gross histologic evaluation
The right ventricular (RV) wall, the left ventricular (LV)
wall, and the interventricular septum (IVS) were dis-
sected. The ratio of the RV to LV plus septal weight
[RV/(LV + IVS)] was calculated as the Fulton index of
RV hypertrophy.
Western blot analysis
Lungs and RV were homogenized at 4 °C in (mM): 150
NaCl, 50 Tris-HCl, 1 EGTA. 1 EDTA, 1 NaF, 1 PMSF, 1
Na3VO4, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxy-
cholate (pH 7.4) supplemented with protease and phos-
patase inhibitor cocktails (Roche). The samples were
centrifuged at 12,000 g for 10 min, and the supernatants
were collected. Protein concentration was measured, and
100 μg of total protein was loaded on a 4–20% gradient
Tris-HCl/SDS polyacrylamide gel, electrotransferred to
nitrocellulose paper, blocked with 5% non-fat dry milk in
20 mM TBS with 0.1% Tween, and incubated with pri-
mary antibodies overnight at 4 °C. Blots were then indir-
ectly labeled using infrared fluorophore conjugated anti-
rabbit and anti-mouse secondary antibodies for 1 h and
visualized with the Odyssey™ Imaging System (Li-Cor).
Equal loading of protein onto each lane in the gel was
confirmed by probing for Vinculin. In the immunoblots,
all samples were run on the same gel or on two gels at
the same time due to the lack of space. The blots were
incubated together with the primary and secondary anti-
bodies and were scanned together with the same laser
intensity. Two adjacent representative lanes from each
group are shown.
Immunohistochemistry and imaging
Lungs were fixed in 4% paraformaldehyde (PFA) in 0.1
M Na2HPO4 and 23 mM NaHPO4 (pH 7.4) for 4 h on
ice. The tissue was then immersed in ice-cold 20% su-
crose in 0.1 M Na2HPO4 and 23 mM NaHPO4 (pH 7.4)
overnight to cryoprotect the tissue, mounted using OCT,
and transversal 4–6 μm sections were obtained with a
cryostat. Tissue sections were stained with immuno-
fluorescence to assess pulmonary vascular remodeling
and Masson trichrome stain to assess pulmonary fibro-
sis. The images were acquired using light microscopes
(Axiovert 135, Zeiss, and Nikon Eclipse E 400) or with a
laser scanning confocal microscope (Olympus). Pulmon-
ary fibrosis was quantified using a grid that divided the
field of view into 100 squares, the number of collage-
nous tissue (blue stain) in the grid was scored as 1
(present) or 0 (absent). Results are expressed as the per-
centage occupied by fibrosis to the total area examined.
Immunofluorescence staining
Lung sections (4–6 μm) were fixed in acetone for 15 min
at –20 °C. The sections were then washed with PBS +
0.1% Triton three times, incubated with 10% normal goat
serum in PBS + 0.1% Triton for 30 min to block the back-
ground. The sections were then incubated with primary
antibodies in PBS + 0.1% Triton + 1% normal goat serum
at 4 °C overnight. The sections were then washed with
PBS + 0.1% Triton three times, incubated with the appro-
priate secondary antibodies in PBS + 0.1% Triton + 1%
normal goat serum at room temperature for 1 h. After
washing the secondary antibodies with PBS + 0.1% Triton
three times, the sections were mounted using ProLong
Gold (Molecular Probes) for imaging with a laser scanning
confocal microscope (Olympus). For assessment of
pulmonary arteriolar wall thickness, only distal pulmonary
arteries less than 50 μm were quantified (3–4 vessels per
mouse). Pulmonary arteriolar wall thickness was calcu-
lated by subtracting diameter of the lumen from total
diameter of the vessel, divided by total diameter of the
vessel. As the diameter of the vessel and lumen are not
usually similar in different directions, pulmonary arteriolar
wall thickness was measured in two different directions
and averaged.
Reagents
Primary antibodies used were anti-smooth muscle actin
(Thermofisher, 701457, 1:200 dilution), anti ERα (Santa
Cruz, Sc-542, 1:1000 dilution), anti ERβ (Thermoscientific,
PA1-31013, 1:1000 dilution), GPR30 (Lifespan Bioscience,
LS-A4272, 1:1000 dilution), and anti Vinculin (Sigma,
V9131, 1:1000 dilution). Secondary antibodies used were
anti-rabbit alexa-fluor 594 (Invitrogen, A11012, 1:1000 di-
lution), goat anti-rabbit-IgG-AlexaFluor680 (Li-Cor, 926-
32211, 1:10000 dilution), and goat anti-mouse-IgG-IR
Dye800CW (Li-Cor, 926-68070, 1:10000 dilution) for
Western immunoblotting.
Statistical analysis
Student’s t test and one-way ANOVA tests were used to
compare between groups using SPSS13.0 for Windows.
When significant differences were detected, individual
mean values were compared by post-hoc tests that
allowed for multiple comparisons. P < 0.05 was con-
sidered statistically significant. Values are expressed as
mean ± SEM.
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Results
In ApoE-deficient mice, young females develop less
severe pulmonary hypertension than MA female mice
Since ApoE-deficient mice are more susceptible to
development of PH, we compared the severity of PH in
WT and ApoE-deficient female mice with aging. In WT
female mice, the severity of PH was similar between
young and MA as RVSP was not significantly different
(RVSP = 38.2 ± 1.2 in young vs. 40.5 ± 8.3 mmHg in
MA, p < 0.05, Fig. 1a). In ApoE-deficient mice, MA
female mice developed significantly worse PH (RVSP =
63 ± 10 mmHg), compared to young females (RVSP; 36 ± 3
mmHg, p < 0.05 vs. MA females, Fig. 1b). ApoE-deficient
MA females also had more severe RV hypertrophy com-
pared to young females (RV hypertrophy index (RV/[LV +
IVS]) = 0.53 ± 0.06 vs. 0.33 ± 0.01, p < 0.05, Fig. 1c). These
results suggest that MA ApoE-deficient mice develop more
severe PH compared to WT mice.
Increased pulmonary vascular remodeling and pulmonary
fibrosis in MA females compared to young female
ApoE-deficient mice
ApoE-deficient MA female mice also demonstrated
increased pulmonary vascular remodeling compared to
young female mice. The pulmonary arteriolar medial
hypertrophy in MA female ApoE-deficient mice was
significantly higher compared to young female mice
(Fig. 2a, b). ApoE-deficient MA female mice also
demonstrated increased pulmonary fibrosis compared
to young female mice as shown by Masson trichrome
staining of lung sections (Fig. 2c, d). These data further
support the severity of PH in ApoE-deficient female mice
as they age.
Exogenous estrogen replacement therapy rescues PH in
aging female ApoE-deficient mice
As ApoE-deficient MA females developed more severe
PH compared to young females, we examined whether
exogenous estrogen (E2) therapy after establishment of
PH could rescue PH in ApoE-deficient mice (Fig. 3a).
The RVSP was significantly reduced by exogenous estro-
gen replacement therapy in MA female ApoE-deficient
mice with PH from day 21 to 30 after MCT (63.3 ± 10.5
in PH vs. 33 ± 5.5 mmHg in E2 group, p < 0.05, Fig. 3b).
In fact, E2 rescued PH in ApoE-deficient MA mice as
the RVSP in E2 treated group was not significantly
different that MA control group that received PBS
(28.3 ± 1.3 mmHg). The RV hypertrophy index was
also reversed by E2 therapy (Fig. 3c). E2 treatment also
significantly reduced the adverse pulmonary arteriolar
hypertrophy (Fig. 3d, e).
Estrogen treatment restores reduced lung estrogen
receptor-beta expression levels in MA females with PH to
levels comparable in young females
E2 exerts its biological actions mainly through estrogen
receptor alpha (ERα), estrogen receptor beta (ERβ), and
GPR30. We examined the expression of estrogen recep-
tors in both lungs and RV in ApoE-deficient MA mice
in control, PH, and E2 treated group. In ApoE-deficient
MA female mice, the expression of ERα was not altered
in the lungs and RV of either CTRL, PH, or E2 treat-
ment groups (Fig. 4a, b). Interestingly, the expression of
ERβ in the lungs was significantly reduced in ApoE-
deficient MA female mice with PH compared to control
(MA CTRL = 1 ± 0.04, MA PH = 0.48 ± 0.11, p < 0.05
vs. MA CTRL, Fig. 4a). Estrogen therapy restored the
expression of ERβ in the lungs of ApoE-deficient MA
A B C
Fig. 1 Development of severe PH in middle-aged female ApoE-deficient mice. a Bar graphs showing right ventricular systolic pressure (RVSP,
mmHg) as a marker of severity of PH in in young (n = 5) and middle-aged (n = 3) WT female mice. b Bar graphs showing RVSP in young (n = 5)
and middle-aged (n = 4) ApoE-deficient female mice. c Bar graphs showing right ventricular hypertrophy index (RV/LV + IVS) as a marker of RV
hypertrophy in young (n = 3) and middle-aged (3) ApoE-deficient female mice. *p < 0.05 vs. young female (t test); Values are expressed
as mean ± SEM
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females (E2 = 0.95 ± 0.12, p < 0.05 vs. MA PH group,
Fig. 4a). The expression of ERβ was not affected in the
RV of MA ApoE-deficient in PH or by E2 treatment
(Fig. 4b). GPR30 was only detected in the RV, and it was
not affected by PH or E2 treatment in MA ApoE-
deficient mice (Fig. 4b, c).
Discussion
The shift of PAH patient population towards post-
menopausal women, the decreases of ApoE in human
PAH lung tissue, and the susceptibility of ApoE-deficient
mice to develop PH, makes ApoE-deficient mice a very
interesting model to study the effects of aging on devel-
opment of PH in females. In this study, we first
compared the effect of aging on severity of PH in ApoE-
deficient mice vs. WT female mice. We discovered
differences between young and middle-aged (MA)
female mice in the development of severe PH only in
ApoE-deficient, but not in WT female mice since ApoE-
deficient MA females developed more severe PH
compared to young females. Next, we examined whether
exogenous estrogen (E2) therapy could rescue estab-
lished PH in ApoE-deficient MA female mice. We found
that exogenous estrogen replacement therapy rescued
PH in ApoE-deficient MA female mice after they had
cessation of estrous cyclicity. The rescue action of E2 in
MA ApoE-deficient mice seems to be linked to lung
estrogen receptor beta (ERβ) restoration.
The role of ApoE has been well established in athero-
sclerosis as ApoE-deficiency results in the development
of atherosclerosis in mice [4]. In the context of PH, pa-
tients have reduced expression of ApoE in their lungs
[11]. ApoE has also been shown to act in an axis along
with two regulators of smooth muscle cell proliferation
and migration, the bone morphogenetic protein 2 (BMP-2)
and peroxisome proliferator-activated receptor γ (PPARγ)
[38–40]. In fact, loss-of-function-mutations in the BMP
receptor II (BMPRII) are linked to the development of
PH [41].
ApoE-deficient mice represent a vulnerable mouse
strain for the development of pulmonary vascular disease
and may serve as a good model for studying the influences
of age on PH in females. Young ApoE-deficient mice have
been shown to develop PH on high fat diet in a sex spe-
cific manner [10]. These sex differences were attributed to
insulin resistance and testosterone’s ability to inhibit the
secretion of adiponectin (a vasoprotective adipocytokine)
in the adipocytes of male mice. Thus, elevated levels of
A B
C D
Fig. 2 Development of pulmonary vascular remodeling and pulmonary fibrosis in middle-aged female ApoE-deficient mice. a Immunofluorescence
images showing α-smooth muscle actin stained pulmonary arterioles in young and middle-aged female ApoE-deficient mice. b Quantification of
arteriolar wall thickness for vessels less than 50 μm in young (n = 3) and MA (n = 3) ApoE-difiecent mice. *p < 0.05 vs. young female (t test). Expressed
as mean ± SEM. c Masson trichrome stained lung sections showing pulmonary fibrosis (blue) in young female and middle-aged female ApoE-deficient
mice. d Quantification of pulmonary fibrosis in young (n = 5) and MA (n = 4) ApoE-deficient mice. *p < 0.05 vs. young female (t test). Values are
expressed as mean ± SEM
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adiponectin in female ApoE-deficient mice accounted for
the less severe vascular phenotype. Treatment of male
ApoE-deficient mice with rosiglitazone (a PPARγ agonist)
resulted in higher plasma adiponectin levels and a
complete regression of PH [10]. Recent studies from our
lab and others have implicated the involvement of
oxidized lipids in the development and progression of PH
[12–14, 42–44]. Hemnes et al. recently provided evidence
for RV lipotoxicity in heritable PAH [45]. Abnormalities
in fatty acid metabolism can be detected in the blood and
myocardium in human PAH and are associated with in
vivo cardiac steatosis and lipotoxicity. Murine data
suggested that lipotoxicity may arise from reduction in




Fig. 3 Rescue of PH in middle-aged female ApoE-deficient mice by exogenous estrogen replacement therapy. a Experimental protocol showing
middle-aged female ApoE-defeicent mice receiving either a single injection of phosphate buffered saline (PBS) for CTRL group at day 0, or single
injection of monocrotaline (MCT, 60 mg/kg) for PH group, or single injection of monocrotaline (MCT, 60 mg/kg) at day 0 followed by estrogen
(E2) treatment from day 21 to 30 in E2 group. b–c Bar graphs showing RVSP (mmHg), and RV hypertrophy index (Weight ratio of RV/LV + IVS)
for ApoE-deficient middle-aged female mice in CTRL (n = 4), PH (n = 4), and E2 (n = 4) treated groups. *p < 0.05 vs. CTRL, #p < 0.05 vs. PH.
d Immunofluorescence images for pulmonary vascular remodeling comparing medial hypertrophy in middle-aged female ApoE-deficient mice of
PH group and E2 treated group. e Quantification of arteriolar wall thickness for vessels less than 50 μm in MA ApoE-deficient mice in PH (n = 3)
and in E2 (n = 4) groups. *p < 0.05 vs. PH (t test). Expressed as mean ± SEM
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increased expression of the lipid transporter CD36 are the
key mechanisms underlying lipid deposition in the
BMPR2 mutant RV, which were exacerbated in the pres-
ence of dietary lipids [47].
We used the already vulnerable ApoE-deficient mice
as a model to study the influence of increasing age on
the development of PH in females. Although females are
more likely to be diagnosed with some forms of PH [17],
they are also protected against PH in different animal
models [18–20], a phenomenon known as the “estrogen
paradox” of PH [21]. This sex difference in experimental
PH has been suggested to be in part due to the protect-
ive effects of estrogen, as ovariectomy exacerbates PH
and pre-treatment/treatment with estrogen and its me-
tabolites attenuates PH and RV dysfunction [22–27].
The cardioprotective effects of estrogen in experimental
models of PH are well documented [48–50]. Previously,
we have shown that estrogen rescues pre-existing severe
PH in rats by restoring lung and RV structure and func-
tion that is maintained even after cessation of estrogen
therapy [24]. Estrogen also protects RV function in the
SuHx model of PAH in mice directly by stimulating RV
contractility and indirectly by protecting against pulmon-
ary vascular remodeling, underscoring the therapeutic
potential of estrogen in PAH [51]. Estradiol improves RV
function in rats with severe angioproliferative PH, suggest-
ing significant RV-protective estrogen receptor-mediated
effects of estrogen [27]. Female SuHx rats exhibited
superior cardiac index than SuHx males. Ovariectomy
worsened SuHx-induced decreases in cardiac index
and SuHx-induced increases in RV hypertrophy and
inflammation. E2 repletion in ovariectomized rats
attenuated SuHx-induced increases in RVSP, RV
hypertrophy, and pulmonary artery remodeling and
improved cardiac index and exercise capacity. Fur-
thermore, E2 repletion ameliorated SuHx-induced
alterations in RV glutathione activation, proapoptotic
signaling, cytoplasmic glycolysis, and proinflammatory
cytokine expression [27]. On the other hand, estrogen
metabolite 16α-hydroxyestrone has been shown to ex-
acerbate Bone Morphogenetic Protein Receptor Type
II (BMPR II) associated PAH [52]. In addition, PAH
has been associated with dysregulated estrogen and
serotonin signaling. Overexpression of the serotonin
transporter in mice results in an estrogen-dependent
development of PAH [53]. The estrogen paradox in
pulmonary hypertension still exists and more research
is needed to explain the molecular basis of this para-
dox [21].
The effect of menopause on the disease severity and
progression in PH has not been extensively investi-
gated. Post-menopausal women with increasing age
have been shown to be at increased risk for the devel-




Fig. 4 Restoration of estrogen receptor beta expression in the lungs
of ApoE-deficient middle-aged female mice with estrogen therapy.
a Representative Western immunoblot images (upper) and bar
graphs (lower) in the lungs from MA ApoE-deficient mice treated
with PBS (control, n = 4), MCT (PH group, n = 3), and MCT with E2
(E2 group, n = 5) showing ERα and ERβ protein expression. *p < 0.05
vs. control, #p < 0.05 vs. PH (one-way ANOVA). Values are expressed as
mean ± SEM. b Representative Western immunoblot images (upper)
and bar graphs (lower) in RV from MA ApoE-deficient mice treated
with PBS (control, n = 4), MCT (PH group, n = 3), and MCT with E2
(E2 group, n = 5) showing ERα, ERβ, and GPR30 expression. Values are
expressed as mean ± SEM. c Western immunoblot images showing
expression of GPR30 only in the RV, but not in the lungs. In all blots
Vinculin was used as loading control and expression of each protein
was normalized to Vinculin
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PH in these patients was prevented by hormone re-
placement therapy [30] suggesting possible endogenous
estrogen depletion and a potential role of exogenous
estrogen replacement therapy. In our study, we also
observed worsening of PH with increasing age only in
ApoE-deficient, but not in WT female mice. The
worsening of PH in only ApoE-deficient MA female
mice points towards the possible interplay between
advancing age, cessation of estrous cyclicity, and in-
creasing oxidized lipids in these mice. This is not
surprising as ApoE is known to inhibit endothelial and
smooth muscle cell proliferation [5, 6] and has anti-
inflammatory and anti-platelet aggregation properties
[9]. ApoE-deficiency leads to enhanced platelet-derived
growth factor signaling, which is important in the
pathobiology of PAH [10]. Exogenous estrogen replace-
ment therapy resulted in complete rescue of cardiopul-
monary hemodynamics and pulmonary vascular
remodeling associated with PH in the ApoE-deficient
MA female mice. As mentioned earlier, others have
attributed sex differences in the development of PH in
female ApoE-deficient mice to elevated levels of adipo-
nectin as female ApoE-deficient mice exhibited less
severe vascular phenotype [10]. On the other hand, in
aging female ApoE-deficient mice, the successful rescue
of PH by exogenous estrogen replacement suggests en-
dogenous estrogen depletion as a main factor, although
a potential contributory role for adiponectin cannot be
ruled out.
Estrogen exerts most of its biological effects via its re-
ceptors, ERα, ERβ, and GPR30. ERβ has been implicated
in the protective effects of estrogen against experimental
PH in rats [24]. ERα has pro-proliferative properties in
certain types of cancers whereas ERβ exerts anti-
proliferative effects [54]. The anti-hypertrophic properties
of E2 in the heart are mediated mainly via ERβ [24, 55].
We observed a downregulation of ERβ in the lungs of
aging female ApoE-deficient mice that was restored by
exogenous estrogen replacement therapy, coinciding with
lowering of RVSP and decrease in pulmonary arteriolar
medial thickness. The expression of ERα was not affected
both in lungs and RV in PH. GPR30 was only detected in
the RV, and it was not affected by PH or by E2 treatment
in ApoE-deficient MA female mice.
Conclusions
In conclusion, middle-aged ApoE-deficient female mice
develop more severe PH compared to younger female
ApoE-deficient mice possibly due to the interplay between
oxidized lipids, and cessation of estrous cyclicity, as a
result of menopause. Exogenous estrogen therapy rescues
PH in aging female ApoE-deficient mice likely through
lung estrogen receptor beta repletion.
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